IRCT20220815055709N1
The effect of using Cannabidiol on the severity of spasticity in MS patients with gait disorders
Effects of oral cannabidiol (CBD) usage on variable severity of spasticity in multiple sclerosis patients with gait problem caused by their spasticity. A Double-Blind Randomised Controlled Trial
Khosro Medisa Teb Company·Phase 3·Iranian Registry Of Clinical Trial·drugCompleted
Study focus
- Disease/Condition
- Multiple sclerosis
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Khosro Medisa Teb Company
- Location
- Iran
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Jan 21, 2023
- End date
- N/A
ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
- Registry
- Iranian Registry Of Clinical Trial
- Trial ID
- IRCT20220815055709N1
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for IRCT20220815055709N1 through Pure Global AI's free database. This Phase 3 trial is sponsored by Khosro Medisa Teb Company and is currently Completed. The study focuses on Multiple sclerosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Iranian Registry Of Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.